anonymous
Guest
anonymous
Guest
ELEPHANT IN THE ROOM; Every SCS company has a problem with long term implanted success rates. Every successful trial is not a long-term successful implant. Nevro has demonstrated superiority, but 20%+ of patients in the Nevro arm of the Senza RCT at 2 years were at less than 50% pain relief. Compare that to 50%+ failure rate (Kumar, North, Boston arm of Senza, SUNBURST) for predicate devices. I have yet to see any prospective, independly audited/controlled studies showing better than a 50% failure rate for non-HF10 therapies.
The brilliant strategy is simple: support every case and do your job to promote good patient selection. Manage expectations.
Correction- Boston Scientific has long term success rate, there SCS therapy is a long term therapy